Strategic Alliances Capitalize on MI’s recent collaborations with Leica Biosystems, Visiopharm, and Standard BioTools to position the company as the go-to multiparametric imaging platform for pharma, CROs, and clinical pathology labs. Develop joint go-to-market plays, co-marketed case studies, and pilot projects focused on RNA-ISH and imaging mass cytometry workflows to win procurement and R&D budgets.

Product Expansion Leverage the HCR Gold, HCR Pro, and HiFi Encoder product lines to offer tiered upgrade paths and bundled service packages that appeal to academic labs, biotech startups, and mid-size pharma groups already using BOND-III or similar automation. Create ROI-focused sales materials highlighting faster workflows, higher multiplexing, and ambient-temperature performance to accelerate adoption.

Clinical Adoption MI’s emphasis on clinical pathology and diagnostics creates opportunities to partner with hospital pathology networks and CLIA labs for validated, in-tissue RNA and protein target detection. Target decision-makers such as pathology directors, clinical scientists, and procurement officers, and propose joint validation studies with OEM partners to accelerate regulatory clearance and routine implementation.

3D Imaging Opportunity The collaboration with Alpenglow Biosciences enables true 3D RNA imaging in intact tissues, expanding the addressable market to whole organs and organoids. Target translational researchers and pharma R&D teams with demonstrations of 3D imaging workflows, and offer combined service-plus-kit packages for end-to-end 3D analysis.

Services Growth With a specialized custom assay design and development service, MI can scale through partnerships and channel ecosystems to reach more universities, biotech companies, and contract labs. Explore reseller and service agreements, remote collaboration, and AI-enabled data analysis partnerships (building on Visiopharm integration) to expand ARR and recurring revenue while validating new assay formats.